Skip to main content
. 2011 Jul 26;105(4):505–512. doi: 10.1038/bjc.2011.278

Figure 2.

Figure 2

Time to tumour progression (A) and overall survival (B) in cohort I (higher dose, n=40) and cohort II (lower dose, n=51) treated with docetaxel and capecitabine. (A) Median time to tumour progression: cohort I, 5.6 months (95% CI: 3.9–7.3), cohort II, 3.7 months (95% CI: 2.5–5.0), P=0.10 (log-rank test). (B) Median overall survival: cohort I, 10.1 months (95% CI: 7.3–13.0), cohort II, 7.2 months (95% CI: 4.1–10.2), P=0.20 (log-rank test).